USANA Health Sciences (NYSE:USNA) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

USANA Health Sciences (NYSE:USNA) released its quarterly earnings results on Tuesday. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19, Zacks reports. The business had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million. USANA Health Sciences had a return on equity of 6.76% and a net margin of 1.16%.

USANA Health Sciences Trading Down 8.2%

Shares of NYSE USNA opened at $18.97 on Thursday. The stock has a market cap of $346.77 million, a P/E ratio of 34.49, a PEG ratio of 0.94 and a beta of 0.67. The business’s fifty day simple moving average is $20.68 and its 200-day simple moving average is $23.60. USANA Health Sciences has a 12-month low of $18.48 and a 12-month high of $38.32.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State of Tennessee Department of Treasury raised its holdings in USANA Health Sciences by 307.8% in the fourth quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock valued at $636,000 after acquiring an additional 22,108 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of USANA Health Sciences by 10.6% in the 4th quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock valued at $1,186,000 after purchasing an additional 5,782 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of USANA Health Sciences by 354.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock worth $2,153,000 after purchasing an additional 85,570 shares during the last quarter. Numerai GP LLC acquired a new position in shares of USANA Health Sciences during the fourth quarter worth $1,027,000. Finally, Millennium Management LLC increased its holdings in USANA Health Sciences by 715.7% in the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock valued at $5,603,000 after buying an additional 250,424 shares during the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $36.00.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.